Brief: UK's MHRA Authorises Novo Nordisk's Wegovy as First GLP‑1 Tablet for Weight Loss

Novo Nordisk A/S

11/06/2026 16:00

June 11 (Reuters) - MHRA:
MHRA: WEGOVY TABLET IS AUTHORISED FOR TREATMENT IN UK ALONGSIDE REDUCED-CALORIE DIET  INCREASED PHYSICAL ACTIVITY
MHRA: WEGOVY PILL APPROVED FOR ADULTS WITH OBESITY WITH BMI OF 30 OR ABOVE
MHRA: WHILST WEGOVY TABLET IS APPROVED FOR USE IN THE UK, IT IS NOT AVAILABLE CURRENTLY VIA THE NHS
MHRA: WEGOVY PILL APPROVED FOR OVERWEIGHT ADULTS WITH BMI BETWEEN 27-30  AT LEAST ONE WEIGHT-RELATED COMORBIDITY
MHRA: AFTER TAKING WEGOVY PILL NO FOOD OR DRINK SHOULD BE TAKEN FOR AT LEAST THIRTY MINUTES
UK'S MHRA: NOVO NORDISK'S SEMAGLUTIDE (WEGOVY) IS THE FIRST GLP-1 TABLET FOR WEIGHT LOSS APPROVED IN UK
MHRA: DECISIONS ON NHS USE OF WEGOVY PILL WILL FOLLOW EVALUATION BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
Further company coverage: [NOVOb.CO]